Dyadic International, Inc. · NASDAQ:DYAI
Dyadic International — 2021 BIO CEO & Investor Digital Conference
26 slides from Dyadic International's conference presentation, Feb 15, 2021
Slide 1: 2021 BIO CEO & Investor Digital Conference
2021 BIO CEO & Investor Digital Conference Dyadic Thermophilic Filamentous Fungus (C1-cells) Recombinant Glycoprotein Antigen Vaccines, Antibodies & Other Therapeutic Protein Product Production Platform February 15, 2021
Slide 2: Safe Harbor Regarding Forward-looking Statements
Safe Harbor Regarding Forward-looking Statements Certain statements contained in this presentation are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including those regarding Dyadic’s expectations, i
Slide 3: Dyadic At A Glance
Dyadic At A Glance Solid Financial Position with Compelling Wholly Market Capitalization $186.6 million (as of 02/12/2021) Owned Products and Partnerships Cash & Investment-grade securities, $30.5 million (as of 9/30/2020) Applying Dyadic’s proprietary & patented C1-cell including accrued interest c
Slide 4: C1 is ideally suited to help meet global demand for multivalent vaccines & antibody cocktails
C1 is ideally suited to help meet the global demand for multivalent vaccines & multi antibody cocktails Building a more efficient biomanufacturing platform to serve a global population more affordably Opportunistic participation in product development of vaccines, biotherapeutics for infectious, onc
Slide 5: Investment Highlights
Investment Highlights Solid Financial Position with $30.5 million in cash and investment securities, no debt1 Top Tier Global Partners and Wholly Owned Programs Broadly applicable to subunit vaccines, therapeutics, enzymes and other peptide, Versatile Platform protein and glycoprotein based products
Slide 6: Addressable C1 Market Opportunities
Addressable C1 Market Opportunities Global and Growing End Market Opportunities Recombinant Subunit Vaccines and Vaccines and Therapeutics for environmental Therapeutic Proteins for Animal health (pandemics) and other biological threats, Global Market size – $11.3 Billion by 20251 including COVID-19
Slide 7: 2021 Dyadic Focus
2021 Dyadic Focus Build On 2020 Scientific Data, BD Success & Momentum Towards first phase I clinical study with C1-RBD antigen against the Covid-19 pandemic Leverage the success in developing C1 antigens against SARS-CoV-2 and animal viruses for ZAPI to expand the rVaccine pipeline for Human and An
Slide 8: 2021 Dyadic Focus - Continue
2021 Dyadic Focus - Continue Continue to prepare for our potential Human Phase 1 Clinical Trial using a Dyadic owned C1-cell manufactured SARS- CoV-2 Receptor Binding Domain (RBD) recombinant antigen vaccine product candidate SARS-CoV-2 Demonstrate Safety & Efficacy (POC) In Humans Expanding the RBD
Slide 9: IIBR Strategic Collaboration Helped To Position Dyadic to Enter Human Clinical Trials
IIBR Strategic Collaboration Helped To Position Dyadic to Enter Human Clinical Trials Israel Institute for Biological Research (IIBR) Demonstrated C1-cell produced SARS-CoV-2 Receptor Binding Domain (RBD) Can Be Manufactured In Large Quantities, At LowAIMCost, Which Neutralizes the COVID-19 Virus Is
Slide 10: Phase I with C1-cell SARS-CoV-2 RBD Recombinant Vaccine in 2021
Phase I with C1-cell SARS-CoV-2 RBD Recombinant Vaccine in 2021 Initiate cGMP manufacturing, conducting toxicology, initiating and completion of an anticipated Human Phase 1 Clinical Trial Of a C1 produced SARS-CoV-2 vaccine candidate. Prove Safety & Efficacy In Humans 10
Slide 11: SARS-CoV-2 (Infectious Disease) Strategy For Global Populations
SARS-CoV-2 (Infectious Disease) Strategy For Global Populations TetraValent Recombinant Variant Antigen SARS-CoV-2 Vaccine Product Candidates Four critical Variant RBDs in preparation for C1-cell manufacturing of Dyadic-4TVATM Antigen-encoded SARS-CoV-2 vaccine candidate 1 week 3 weeks 1 week 2 week
Slide 12: ZAPI success leads to fully funded collaborations with global animal & human health companies
ZAPI success leads to fully funded collaborations with several leading global animal & human health companies and governmental agencies AIM EU Government ZAPI Collaboration Further Positions C1 Products For Potential Human Clinical Trials Zoonoses Anticipation Preparedness Initiative (ZAPI) • 2015 –
Slide 13: Platform R&D / Technology Transfer
Platform R&D / Technology Transfer Glyco-Protein Engineering of C1-cells: Advance Dyadic’s Nivolumab (Opdivo®) Technology Transfer Biosimilar MAbAs Proof of Concept for Production of mAbs Progress 2020 conducted Tech-Transfer of C1 into a Protease Engineering (i.e., protease deletions) of C1-cells n
Slide 14: Human Biopharmaceutical Programs - Nivolumab (Opdivo)
• UCB’s approved Cimzia, which is indicated for various rheumatic diseases Human Biopharmaceutical Programs - Nivolumab (Opdivo®) • C1 has produced certolizumab (Cimzia) in single use bioreactors or in stainless steel a Biosimilar mAb Candidate bioreactors with equivalent yields Anti-Cancer mAb, (i.
Slide 15: C1-Cell High Value Recombinant Protein Production Platforms Competitive Advantages
C1-CELL HIGH VALUE RECOMBINANT PROTEIN PRODUCTION PLATFORMS COMPETITIVE ADVANTAGES
Slide 16: Filamentous Fungus C1-Cell High Level Protein Production
Filamentous Fungus C1-Cell High Level Protein Production High Purities & Exceptional Yields/Stabilities with Scalable Benefits for Protein Based Product Manufacturing C1-cells are thermophilic filamentous fungi with highly desirable growth and manufacturing properties C1 initially developed to produ
Slide 17: C1-Cell Recombinant Protein Products With Competitive Advantages
C1-Cell Recombinant Protein Products With Competitive Advantages Robust Recombinant Protein Production Platform Offers Competitive Advantages Over Existing Techs High retention of target secreted protein(s) or other C1-cell bioproduct(s) through Purities downstream processing No viral or endotoxins
Slide 18: C1-Cell Recombinant Protein Production Broadly Applied For Biologics
C1-Cell Recombinant Protein Production Broadly Applied For Biologics C1-Cells Enable Commercial Manufacture Of Rapid, Cost-Effective, High Value, Safe, Effective Protein Products High Yields and Purities Demonstrated for Therapeutic Monoclonal Antibodies (mAbs) and Vaccine Antigen GlycoProteins1 Fc-
Slide 19: Returns on Investments from Focused Business Development
RETURNS ON INVESTMENTS FROM FOCUSED BUSINESS DEVELOPMENT
Slide 20: Business Development Strategy
Business Development Strategy External development programs help advance C1 recombinant protein platform and fund R&D initiatives AIM Co-Development /Technology Licensing Internal Dyadic Product Development Allows Dyadic to develop and advance C1 recombinant Dyadic funds high value product candidate
Slide 21: Investment Highlights
Investment Highlights Solid Financial Position with $30.5 million in cash and investment securities, no debt1 Top Tier Global Partners and Wholly Owned Programs Broadly applicable to subunit vaccines, therapeutics, enzymes and other peptide, Versatile Platform protein and glycoprotein based products
Slide 22: Management & Directors With Track Record Of Success/Value Creation
Management & Directors With Track Record Of Success/Value Creation Highly Energized Professional Management Team with Deep Industry Expertise & Products In Market Active Board with Decades of Relevant Experience in Biomanufacturing Mark Emalfarb Ronen Tchelet CSO Founder, CEO 20+ years in BioPharmac
Slide 23: Global Need For Rapid, Safe, Scalable Vaccine Antigen & Antibody Manufacturing
Global Need For Rapid, Safe, Scalable Vaccine Antigen & Antibody Manufacturing SARS-CoV-2 pandemic highlights unmet needs for rapid MonoValent, DiValent, Trivalent or MultiValent Unmet Med Needs Antigen Vaccine(s), Antibodies and other Therapeutic Recombinant Proteins; not only safe and effective, b
Slide 24: C1-Cell Manufacture SARS-CoV-2 Global Recombinant Vaccine & Monoclonal Antibody Strategic Programs
C1-Cell Manufacture SARS-CoV-2 Global Recombinant Vaccine & Monoclonal Antibody Strategic Programs Nine development programs carried out globally; Additional Programs Under Discussion Asia 1 Program 2 Programs 4 Programs 1 Program North America 1 Program India South America Africa Australia & Middle
Slide 25: Dyadic International Summary & Vision
Dyadic International Summary & Vision • To accelerate the adoption & use of C1-Cells to speed the development, lower the cost, improve the performance while providing the necessary quantities of vaccines & drugs to a global population more affordably. • Strategy to deliver thermophilic filamentous f
Slide 26: Contact: [email protected]
Contact: [email protected] North America India South America Africa Australia (including Middle East) www.dyadic.com 26 26
Dyadic International — 2021 BIO CEO & Investor Digital Conference on 6ix